NCT00582166View on ClinicalTrials.gov

Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance

PHASE2TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 25, 2005

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

Ibritumomab Tiuxetan (Zevalin) + Rituximab

Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression

Trial Locations (1)

53792

University Of Wisconsin, Madison

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Wisconsin, Madison

OTHER